Login    Join free Add to favorites    中文
home > news > Final Agenda for 19th Annual Drug Discovery Summit
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Final Agenda for 19th Annual Drug Discovery Summit

hits:357     Date:03/23/18
The drug discovery industry has dramatically changed over the last decade. Join over 300 high-profile delegates at Oxford Global鈥檚 19th Annual Drug Discovery Summit, Berlin on the 7-8th June 2018 to explore the latest advancements and hear from leading industry pioneers.
 
Bringing you the latest in drug discovery innovations and strategies, discovery enabling technologies and novel drug targets for key therapeutic areas, you can expect to benefit from presentations by Chief Scientific Officers, Vice Presidents and Directors of leading organisations in the field.
 
New for 2018! We are covering a range of new areas such as new modalities, natural products and drug-target kinetics in discovery.
 
Conference highlights include:
 
  • New Modalities For Treatment Of Cardiovascular & Metabolic Diseases
    Malin Lemurell, from AstraZeneca
  • Identification & Drug Discovery To Illuminate Novel Patient Biology      
    Vivek K Vishnudas from Berg
  • Drug Discovery Approaches To Protein Misfolding & Aggregation Diseases
    Magnus Walter from Eli Lilly
  • Technology To Support Safety Optimisation For Early Drug Discovery   
    Ray Kemper from Vertex

 

The event will once again be co-located with our highly esteemed 6th Annual Discovery Chemistry & Drug Design Congress which will be covering the latest in medicinal and computational chemistry and drug design. New for 2018! We鈥檒l be including deep dive sessions on DNA encoded libraries and hear updates on protein-protein interactions in drug discovery.
 
Key presentations include:
 
  • Encoded Library Technologies In Drug Discovery  
    Christoph Dumelin from Novartis
  • Molecular Availability And Accessibility - Measuring & Understanding Cellular Drug Concentrations During Lead Optimisation      
    Mike Hann from GlaxoSmithKline
  • Challenges With Protein-Protein Interaction (PPI) Modulation For Immunology  
    Thorsten Thormann from Leo Pharma
 
View Agenda: http://bit.ly/2mqWK5m
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙